Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After Its 261% One-Year Surge?

• Investors may be wondering if Indivior Pharmaceuticals at US$39.60 is still offering value after its strong run, or if most of the upside is already reflected in the price.
• The stock has returned 7.7% over the last week, 30.0% over the last month, 10.8% year to date and 260.7% over the last year. This naturally raises questions about how the risk reward trade off now looks.
• Recent news around Indivior Pharmaceuticals has focused on its position in the pharmaceuticals space and how the market is reassessing companies in this sector. This backdrop helps explain why investors are paying closer attention to pricing, quality of earnings and potential future growth drivers when they look at the stock.
• Indivior Pharmaceuticals currently holds a valuation score of 4 out of 6. The rest of this article will compare what different valuation methods suggest about the stock and then finish with a way to look at value that goes beyond simple ratios and models.

Indivior Pharmaceuticals delivered 260.7% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Indivior Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s dollars. It is essentially asking what the stream of future cash the business might generate is worth right now.

For Indivior Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $170.4 million, so the focus here is on the expected future cash generation rather than the most recent year alone. Analyst and extrapolated projections show free cash flow reaching $636.2 million in 2035, with key forecast years such as 2026 at $385.9 million and 2030 at $536.5 million. All of these figures are in US$ and are below $1b, so they are best thought of as hundreds of millions per year in potential cash to equity holders.

When all those projected cash flows are discounted back, the estimated intrinsic value comes out at $106.38 per share versus a current share price of $39.60. This implies an intrinsic discount of 62.8%.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Indivior Pharmaceuticals is undervalued by 62.8%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Indivior Pharmaceuticals.

Approach 2: Indivior Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand because it links what you pay for the stock to the earnings the business is already generating. It gives you a quick sense of how many dollars of share price equate to one dollar of current earnings.

What counts as a “normal” P/E ratio depends on how the market views the company’s growth potential and risk. Higher expected earnings growth or lower perceived risk can support a higher multiple, while slower growth or higher risk usually points to a lower, more modest P/E.

Indivior Pharmaceuticals is trading on a P/E of 19.16x, compared with the Pharmaceuticals industry average of about 16.05x and a peer group average of 54.95x. Simply Wall St’s Fair Ratio for Indivior Pharmaceuticals is 17.50x, which is its proprietary view of what the P/E could be given factors such as earnings growth, profit margins, industry, market cap and key risks. This Fair Ratio aims to be more tailored than a simple comparison with peers or the broad industry, because it adjusts for the company’s specific characteristics rather than assuming all stocks in the sector deserve similar multiples.

On this basis, the current P/E of 19.16x is above the Fair Ratio of 17.50x, which points to the stock looking overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Indivior Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a simple story behind your numbers, where you set assumptions for Indivior Pharmaceuticals’ future revenue, earnings and margins, link that story to a financial forecast, see an implied Fair Value, and then compare it with today’s price to judge whether the stock fits your own buy or sell rules. All of this is within a tool on the Community page that updates as new news or earnings arrive. For example, one investor might build a more optimistic Indivior Pharmaceuticals Narrative that lines up with a Fair Value of about US$50.00, while another takes a more cautious view closer to US$35.00, and both perspectives sit side by side so you can quickly see how different beliefs about the same company lead to different Fair Values.

For Indivior Pharmaceuticals, however, we will make it really easy for you with previews of two leading Indivior Pharmaceuticals Narratives:

🐂 Indivior Pharmaceuticals Bull Case

Fair Value: US$50.00

Implied discount vs last close: about 20.8% undervalued

Revenue growth assumption: 3.78%

• Focuses on SUBLOCADE’s roughly 75% share of the U.S. long acting injectable category and the company’s decision to concentrate resources on this product.
• Assumes margin expansion as operating expenses are capped at US$450 million in 2026 and nonessential spend is reduced by at least US$150 million a year.
• Builds in analyst expectations for revenue growth, profit margin expansion to 45.2% and earnings of US$596.3 million by around 2029, together with a lower future P/E of 12.9x.

🐻 Indivior Pharmaceuticals Bear Case

Fair Value: US$37.86

Implied premium vs last close: about 4.6% overvalued

Revenue growth assumption: 1.67%

• Frames Indivior as closer to fairly priced, with a consensus view that links modest revenue growth and margin expansion to a Fair Value around US$37.86.
• Assumes earnings reach US$477.5 million by about 2028 with profit margins rising to 38.5% and the stock trading on a future P/E of 12.2x.
• Highlights that the gap between the current share price and the consensus target is relatively small, so outcomes are sensitive to how SUBLOCADE adoption, cost savings and market conditions play out.

These two narratives give you a clear bullish and more cautious frame for Indivior Pharmaceuticals so you can decide which set of assumptions feels closer to your own view on the stock, its risks and its potential rewards.

Do you think there’s more to the story for Indivior Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com